Seattle-based Neoleukin Folded into New York Biotech After Merger 


Neoleukin Therapeutics, a biotech company that spun out of the University of Washington in 2019, finalized its merger with Neurogene, a biotech firm based in New York on December 19.  Neurogene will pass its name down to the newly merged company and will assume management responsibilities, along with 84% of company shares. Along with the merger, Neurogene also announced an influx of $95M in private funding. The combined company will prioritize Neurogene’s mission of developing a treatment pipeline for neurological disease.